

Rheumatoid Arthritis

Study to Describe Real World Drug Retention Rate of the Tocilizumab at One Year

| | | |
|----------------------------------|-------------------------------------|--|
| Trial Status Completed | Trial Runs In 1 Countries | Trial Identifier NCT02608112 ML29256 |
|----------------------------------|-------------------------------------|--|

The source of the below information is the publicly available website [ClinicalTrials.gov](https://clinicaltrials.gov). It has been summarised and edited into simpler language.

Trial Summary:

This multicenter, prospective, non-interventional study is designed to obtain an accurate estimation of the drug retention rate of Tocilizumab (TCZ) Subcutaneously (SC) under real-world conditions in participants with moderate to severe rheumatoid arthritis (RA).

| | |
|-------------------------------------|---------------------|
| Hoffmann-La Roche Sponsor | N/A Phase |
|-------------------------------------|---------------------|

| |
|---|
| NCT02608112 ML29256 Trial Identifiers |
|---|

Eligibility Criteria:

| | | |
|----------------------|---------------------------|---------------------------------|
| Gender All | Age >= 18 Years | Healthy Volunteers No |
|----------------------|---------------------------|---------------------------------|
